AFT Pharmaceuticals recently reported its FY19 results; the highlights were improving margins, as well as operating profitability for the year. Revenue grew 4.9% over 2018 while gross profit grew by 15.4% following the divestment of relatively low-margin hospital products in New Zealand and Australia. Lower SG&A and R&D spending allowed the company to report an operating profit of NZ$6.2m and the company is currently targeting an operating profit of between NZ$9m and NZ$12m for FY20.<
28 May 2019
AFT Pharmaceuticals - Operating profitability achieved
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
AFT Pharmaceuticals - Operating profitability achieved
AFT Pharmaceuticals recently reported its FY19 results; the highlights were improving margins, as well as operating profitability for the year. Revenue grew 4.9% over 2018 while gross profit grew by 15.4% following the divestment of relatively low-margin hospital products in New Zealand and Australia. Lower SG&A and R&D spending allowed the company to report an operating profit of NZ$6.2m and the company is currently targeting an operating profit of between NZ$9m and NZ$12m for FY20.<